Cite
Complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to CD‐19 chimeric antigen receptor T‐cell therapy.
MLA
Tambaro, Francesco Paolo, et al. “Complete Remission in Refractory Acute Lymphoblastic Leukemia Using Blinatumomab after Failure of Response to CD‐19 Chimeric Antigen Receptor T‐cell Therapy.” Clinical Case Reports, vol. 8, no. 9, Sept. 2020, pp. 1678–81. EBSCOhost, https://doi.org/10.1002/ccr3.2918.
APA
Tambaro, F. P., Khazal, S., Nunez, C., Ragoonanan, D., Tewari, P., Petropoulos, D., Kebriaei, P., Wierda, W. G., & Mahadeo, K. M. (2020). Complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to CD‐19 chimeric antigen receptor T‐cell therapy. Clinical Case Reports, 8(9), 1678–1681. https://doi.org/10.1002/ccr3.2918
Chicago
Tambaro, Francesco Paolo, Sajad Khazal, Cesar Nunez, Dristhi Ragoonanan, Priti Tewari, Demetrios Petropoulos, Partow Kebriaei, William George Wierda, and Kris Michael Mahadeo. 2020. “Complete Remission in Refractory Acute Lymphoblastic Leukemia Using Blinatumomab after Failure of Response to CD‐19 Chimeric Antigen Receptor T‐cell Therapy.” Clinical Case Reports 8 (9): 1678–81. doi:10.1002/ccr3.2918.